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Conclusions: The number of entry tears detected on the ﬁrst
computed tomography angiography (CTA) study following acute type B
aortic dissection is a signiﬁcant predictor of subsequent aortic growth.
Summary: Patients with uncomplicated acute type B aortic dissection
treated conservatively by antihypertensive treatment have in-hospital mor-
tality rates between 1% and 10%. Favorable initial outcomes, however, are
mitigated by medium-term and long-term problems related to the aorta,
such as aneurysm growth and rupture. These delayed problems result in sur-
vival rates of 56% to 92% at 1 year and 48% to 82% at 5 years (Tsai TT et al,
N Engl J Med 2007;357:349-59). It is thought that impaired outﬂow of the
false lumen or increased inﬂow to the false lumen can lead to an increase in
mean and diastolic pressure in the false lumen. Acutely, this may lead to true
lumen collapse and malperfusion and, on a more long-term basis, elevated
pressure in the false lumen with increased aortic growth and risk for aortic
rupture. The authors sought to determine whether the number of entry
tears detected between the true and false lumen might help predict which
patients with acute type B aortic dissection are at increased risk for late aortic
dilation. The authors evaluated acute type B aortic dissection patients with
uncomplicated dissection. Patients with a CTA obtained at clinical presen-
tation and another CTA at least 90 days after medical treatment were
included from the years 2005 to 2010. Aortic diameters were measured
at ﬁve levels on the base line CTA and on last available CTA with annual
aortic growth rates calculated. The number of entry tears between the
true and false lumen were also determined. Number of entry tears and
the location of entry tears in the aorta were then compared with aortic
growth rates. There were 60 patients with 243 dissected segments. Mean
growth rates during follow-up (median, 23.2 months, range, 3-132
months) were higher in patients with one entry tear (5.6 6 8.9 mm) than
those with two (2.1 6 1.7 mm; P ¼ .001) and three entry tears (mean,
2.2 6 4.1; P ¼ .010). Distance of the primary entry tear from the left sub-
clavian artery did not have an effect on aortic growth rate (median, 38 mm;
interquartile range, 24-137 mm; P ¼ .434).
Comment: The data are somewhat limited by the fact that in the clin-
ical setting, imaging of acute aortic dissections may vary with respect to the
cardiac cycle, conﬁguration of the aortic lumen, and changes of the ﬂap dur-
ing systole and diastole. Dynamic CT scanning rather than static scanning
used in this study may have also identiﬁed additional entry tears. The aortic
dissection process is complex and in some respects the data may argue for
more routine use of dynamic CT imaging in patients with acute type B
aortic dissection. It is only through improved understanding of the dissec-
tion process that better selection of patients with acute type B aortic dissec-
tion for immediate intervention will be determined.
Flow Reversal Versus Filter Protection: A Pilot Carotid Artery
Stenting Randomized Trial
de Castro-Afonso LH, Abud LG, Rolo JG, et al. Circ Cardiovasc Interv
2013;6:552-9.
Conclusions: During carotid artery stenting (CAS) using a femoral
approach, ﬁlter protection is more effective than ﬂow reversal in reducing
ischemic brain lesions.
Summary: Embolic protection devices (EPDs) have been associated
with improved clinical outcomes in CAS (Kastrup A et al, Stroke
2003;34:813-9; and Garg N et al, J Endovasc Ther 2009;16:412-27).
The most widely used EPDs are distal protective techniques using ﬁlter de-
vices. An alternative strategy to protect the brain during CAS procedures is
to use proximal protective techniques. With proximal protection, common
and external carotid arteries are occluded promoting ﬂow arrest or ﬂow
reversal of the target internal carotid artery. Theoretically, this establishes
brain protection to cross and treat the carotid stenosis during CAS. This pi-
lot trial was designed to compare ﬂow reversal vs ﬁlter protection during
CAS using femoral access techniques. The trial was a randomized,prospective, open-label (blinded outcomes), single-center, superiority trial.
Patients undergoing CAS were randomly enrolled to have either ﬂow
reversal or ﬁlter protection during the procedure. The primary end points
of the study were the incidence, number, and size of new ischemic brain le-
sions after CAS. Secondary end points included major adverse cardiac and
cerebrovascular events, transient ischemic attack, and deﬁnitive ischemic
brain lesions on ﬂuid-attenuated inversion recovery magnetic resonance im-
aging at the 3-month follow-up. 3T magnetic resonance imaging was used
to assess ischemic brain lesions. Neurologic outcomes were evaluated using
the modiﬁed Rankin Scale and the National Institutes of Health Stroke
Scale. There were 40 consecutive patients randomly assigned in the study.
Compared with ﬂow reversal (n ¼ 21), ﬁlter protection (n ¼ 19) resulted
in a signiﬁcant reduction in the incidence (15.8% vs 47.6%; P ¼ .03), num-
ber (0.73 vs 2.6; P ¼ .05), and size (0.81 vs 2.23 mm; P ¼ .05) of new
ischemic brain lesions. One patient in each group presented with a transient
ischemic attack at the 3-month follow-up. No major adverse cardiac or
cerebrovascular events occurred in the hospital or at the 3-month follow-
up period.
Comment: One potential criticism of the study will be the learning
curve effect. The primary operator for the trial apparently has performed
450 CAS procedures, of which 412 cases used ﬁlter devices and only 27
cases used proximal protection devices with ﬂow arrest and 12 cases with
proximal protection and ﬂow reversal prior to randomization in the trial.
This was also a single-institution study. However, the authors did have pre-
cise and speciﬁc predetermined end points for their study and the trial did
demonstrate ﬁlter protection was more effective than ﬂow reversal in
reducing ischemic brain lesions during CAS. The results are what they
are, but obviously larger trials will be necessary to conﬁrm the author’s ﬁnd-
ings and the clinical implications of these ﬁndings.
Management and Outcomes of Major Bleeding During Treatment
With Dabigatran or Warfarin
Majeed A, Hwang H-G, Connolly SJ, et al. Circulation 2013;124:2325-32.
Conclusions: Patients experiencing major bleeding on dabigatran
require more red cell transfusions, less plasma, shorter intensive care unit
stays, and have a trend to lower mortality compared to those with major
bleeding on warfarin.
Summary: Dabigatran is approved in more than 80 countries in the
world for stroke prevention in patients with atrial ﬁbrillation. There is supe-
rior stroke reduction with dabigatran 150-mg twice daily and noninferior
stroke prevention with dabigatran 110 mg twice daily compared with
warfarin with a target international normalized ratio of 2 to 3 (Connolly
SJ et al, N Engl J Med 2009;361:1139-51). With respect to bleeding, major
bleeding in patients treated with dabigatran 150-mg twice daily is similar to
that in patients treated with warfarin. In patients treated with dabigatran
110-mg twice daily, major bleeding is less than in patients treated with
warfarin. In patients with venous thromboembolism, there is also a lower
rate of bleeding with dabigatran 150-mg twice daily compared with warfarin
with a target international normalized ratio of 2.0 to 3.0 (Schulman S et al,
N Engl J Med 2009;361:2342-52). Warfarin has a half-life of 36 to 48
hours, but it’s anticoagulant effect can be reversed within 10 to 20 minutes
by prothrombin complex concentrates and within 6 to 12 hours by vitamin
K (Holbrook A et al, Chest 2012;141(2 Suppl):e152S-84S). Dabigatran
does not have an antidote and has a half-life of 12 to 14 hours (Stangier
J et al, Br J Clin Pharmacol 2007;64:292-303). In patients with life-threat-
ening bleeding on dabigatran, hemodialysis might help restore hemostasis in
combination with activated charcoal to prevent gastrointestinal absorption
of recently ingested drug, as well as administration of prothrombin concen-
trates or recombinant factor VII. Evidence as to the efﬁcacy of reversal
of dabigatran, however, is limited primarily to experimental and animal
studies and isolated case reports. The objective of the study presented
here was to describe management of major bleeding and outcomes after
bleeding in large phase III trials evaluating the efﬁcacy and safety of long-
term dabigatran ($6 months) compared with warfarin. Two independent
investigators reviewed bleeding reports from 1034 individuals with 1121871
